Literature DB >> 31037971

Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.

Pushpendra Goswami1, Esther N Oliva2, Tatyana Ionova3, Roger Else4, Jonathan Kell5, Adele K Fielding6, Daniel M Jennings7, Marina Karakantza8, Saad Al-Ismail9, Jack Lyness9, Graham P Collins10, Stewart McConnell8, Catherine Langton8, Magda Jabbar Al-Obaidi11, Metod Oblak11, Sam Salek1.   

Abstract

Aim: To determine measurement equivalence of paper and electronic application of the hematological malignancy-patient-reported outcome (HM-PRO), a specific measure for the evaluation of patient-reported outcomes in HMs. Patients & methods: Following International Society of Pharmacoeconomics and Outcomes Research ePRO Good Research Practice Task Force guidelines, a total of 193 adult patients with different HMs were recruited into a multicenter prospective study. The paper and the electronic version of the instrument were completed in the outpatient clinics in a randomized crossover design with a 30 min time interval to minimize the learning effect. Those who completed the paper version first, completed the electronic version after 30 min and vice versa. Instrument version and order effects were tested on total score of the two parts of the HM-PRO (Part A: quality of life and Part B: signs & symptoms) in a two-way ANOVA with patients as random effects. Intraclass correlation coefficients (95% CI) and Spearman's rank correlation coefficients were used to evaluate test-retest reliability and reproducibility. The effects of instrument version and order were tested on total score of the two parts of HM-PRO.
Results: The questionnaire version and administration order effects were not significant at the 5% level. There were no interactions found between these two factors for HM-PRO (Part A [quality of life]; p = 0.95); and (part B [signs and symptoms]; p = 0.72]. Spearman's rank correlation coefficients were greater than 0.9, and intraclass correlation coefficients ranged from 0.94 to 0.98; furthermore, the scores were not statistically different between the two versions, showing acceptable reliability indexes. Noteworthy, the difference between the completion time for both paper (mean = 6:38 min) and electronic version (mean = 7:29 min) was not statistically significant (n = 100; p = 0.11). Patients did not report any difficulty in completing the electronic version during cognitive interviews and were able to understand and respond spontaneously.
Conclusion: Measurement equivalence has been demonstrated for the paper and electronic application of the HM-PRO.

Entities:  

Keywords:  HM-PRO; hematological malignancy; paper/electronic PRO

Mesh:

Year:  2019        PMID: 31037971     DOI: 10.2217/cer-2018-0108

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  3 in total

Review 1.  Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers.

Authors:  Maribel Salas; Mackenzie Henderson; Angelika Wientzek-Fleischmann; Zahidul Islam; Nora Tu; Aikaterini Bilitou; Maggie Elsharkawy; Ulf Stellmacher
Journal:  Front Pharmacol       Date:  2020-07-24       Impact factor: 5.810

2.  Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.

Authors:  Pushpendra Goswami; Esther N Oliva; Tatyana Ionova; Roger Else; Jonathan Kell; Adele K Fielding; Daniel M Jennings; Marina Karakantza; Saad Al-Ismail; Graham P Collins; Stewart McConnell; Catherine Langton; Magda J Al-Obaidi; Metod Oblak; Sam Salek
Journal:  Front Pharmacol       Date:  2020-10-20       Impact factor: 5.810

3.  Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.

Authors:  Pushpendra Goswami; Esther N Oliva; Tatyana Ionova; Roger Else; Jonathan Kell; Adele K Fielding; Daniel M Jennings; Marina Karakantza; Saad Al-Ismail; Graham P Collins; Stewart McConnell; Catherine Langton; Magda J Al-Obaidi; Metod Oblak; Sam Salek
Journal:  Front Pharmacol       Date:  2020-09-08       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.